High amounts of injected vitamin C may delay the growth of many types of tumours and boost the anticancer power of immune checkpoint therapies, report Italian oncologists.
Roche AGs has paid US$30m upfront in a potential US$1.7bn deal to get access to Bicycle Therapeutics plcs technology platform to target immune checkpoints.
Widespread use of human induced pluripotent stem cell (hiPSC) derived mature cell types is restricted by complex differentiation protocols and inefficient reprogramming methods. By applying a novel gene engineering approach, opti-oxTM, to cellular reprogramming these restrictions have been largely overcome. This proprietary technology enables precise reprogramming and homogeneous differentiation of entire stem cell cultures into any desired cell type.
Negotiations of the EU Council on the EU’s seven-year budget have failed, putting R&D funding at risk for significant cuts.
Royal DSM NV has entered the growing market of human milk oligosaccharides (HMO) taking over the producer of recombinant 2-fucosyl lactose, Danish Glycom A/S.
US-German immunooncology specialist Immatics Biotechnologies GmbH has licensed two of its TCR-T programs to GlaxoSmithKline for US$50m upfront.
Univercells S.A. cashes in up to €50m from the KKR subsidiary Gamma Bioscience to advance its gene and cell therapy manufacturing platform.
Shortly before a EU health ministers discuss the spread of the Chinese coronavirus, EU diagnostic labs have considered themselves prepared for a possible Sars-CoV-2 epidemic.
Co-founder Fiona Withey is the new Chief Executive Officer of TrakCel, a software developer of orchestration systems for advanced therapies. Co-founder Ravi Nalliah was appointed to the role of Chief Strategy Officer.